What Is Tranexamic Acid?
Tranexamic acid (TXA) was originally developed as a hemostatic drug — a medication used in surgery and obstetrics to control excessive bleeding. Its entry into dermatology began in the late 1970s, when Korean and Japanese clinicians observed that patients taking oral TXA for bleeding conditions experienced an unexpected side effect: their melasma improved.
What sets TXA apart from most brightening actives is its mechanism. While vitamin C, kojic acid, arbutin, and azelaic acid all target tyrosinase directly, tranexamic acid works upstream — intercepting the UV/inflammation signaling pathway that triggers melanocytes in the first place. This makes it especially effective for melasma and PIH, two conditions that are notoriously difficult to treat because of their inflammatory roots.
How It Works
When UV radiation hits the skin, keratinocytes release plasminogen activator, which converts plasminogen into plasmin. Plasmin then drives melanin overproduction through two parallel routes:
- Releases arachidonic acid → increases prostaglandin synthesis → stimulates melanocytes
- Promotes α-MSH secretion → activates MITF transcription factor → increases melanin synthesis
Tranexamic acid blocks the lysine-binding sites on plasminogen, preventing its activation into plasmin. This single blockade interrupts both downstream pathways simultaneously.
This upstream mechanism is why TXA works well on both melasma (UV + hormonal trigger) and PIH (inflammation trigger) — and why it synergizes with tyrosinase inhibitors like niacinamide and vitamin C rather than overlapping with them.
Clinical Evidence
Oral Tranexamic Acid
The strongest clinical record belongs to the oral form. The standard dose is 250mg twice daily, and multiple controlled trials have shown significant melasma improvement at 12 weeks.
In the landmark Na & Choi (2016) randomized, double-blind, placebo-controlled multicenter trial, the oral TXA group achieved a 49.5% reduction in MASI (Melasma Area and Severity Index) scores at 12 weeks, compared to only 17.9% in the placebo group. Benefits extend beyond melasma to solar lentigines and PIH.
Oral TXA is a prescription medication. It is contraindicated in patients with a history of thromboembolism.
Topical Tranexamic Acid
The 2–5% topical form has lower bioavailability than oral but an excellent safety profile that supports long-term use. Kim et al. (2003) demonstrated significant MASI improvement with topical 2% TXA over 12 weeks. Combination formulations pairing TXA with niacinamide or alpha-arbutin have shown faster results than single-ingredient use.
Form and Concentration Guide
| Form | Concentration | Availability | Key Consideration |
|---|---|---|---|
| Topical cosmetic | 2–5% | OTC | Safe for long-term use; slower results |
| Topical pharmaceutical | 5–10% | Prescription | Faster results; requires physician |
| Oral medication | 250–500mg twice daily | Prescription only | Most potent for melasma; thrombosis contraindication |
| Combined with microneedling | Topical + procedure | Clinic | Enhanced dermal penetration |
For most people, the practical starting point is a topical 2–5% product used consistently with daily SPF50+ sunscreen.
Comparing Brightening Ingredients
| Ingredient | Primary Mechanism | Melasma | PIH | Irritation | Combinability |
|---|---|---|---|---|---|
| Tranexamic Acid | Plasmin pathway blockade | ★★★★★ | ★★★★☆ | Very low | Excellent with most actives |
| Niacinamide | Melanin transfer blockade | ★★★☆☆ | ★★★★☆ | Very low | Synergistic with TXA |
| Vitamin C | Tyrosinase inhibition + melanin reduction | ★★★★☆ | ★★★☆☆ | Medium | Use AM; combine well |
| Azelaic Acid | Selective tyrosinase inhibition | ★★★☆☆ | ★★★★☆ | Low–medium | Compatible |
| Alpha-Arbutin | Tyrosinase inhibition | ★★★★☆ | ★★★☆☆ | Low | Compatible |
| Retinol | Cell turnover acceleration | ★★★☆☆ | ★★★★☆ | High | Alternate evenings |
Tranexamic acid’s unique combination of high melasma efficacy and very low irritation makes it one of the most accessible brightening actives for sensitive skin, or for those who can’t tolerate retinol or high-strength AHA.
How to Use
Morning or evening: No photosensitivity, so either routine works. For melasma, morning use must be paired with SPF50+ sunscreen — without it, ongoing UV exposure re-triggers the plasmin pathway and negates results.
Layering order: Cleanse → Toner → Tranexamic acid serum → Moisturizer → Sunscreen (morning).
Skin type: Very low irritation means it’s suitable for sensitive skin, rosacea-prone skin, and those who’ve had difficulty tolerating more aggressive brighteners.
Timeline: With topical 2–5%, expect visible improvement at 8–16 weeks of consistent use. Oral forms typically show results within 4–8 weeks.
Frequently Asked Questions
Related guides: Brightening Ingredients Overview — compare tranexamic acid with niacinamide, vitamin C, and arbutin | Niacinamide — synergistic brightening pairing | Pigmentation Complete Guide — melasma and PIH treatment strategy